Drug intelligence / Profile preview

Lysophosphotidylserine

Development stage: Unknown
Modality: Small Molecules
Administration: Oral, Intravenous, Subcutaneous, Parenteral

Overview

Lysophosphotidylserine is a lysophospholipid. In a cell-free system, it was found to have no significant effect on the activity of partially purified cabbage phospholipase D (PLD), distinguishing it from other related lysophospholipids like lysophosphatidylethanolamine (LPE) which inhibited PLD activity.

Targets

P2RY10 (P2Y10 receptor)GPR34 (G protein-coupled receptor 34)GPR174 (G protein-coupled receptor 174)

Beyond the preview

Go deeper on Lysophosphotidylserine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Lysophosphotidylserine.

Explore the full profile